• Scientist (AgenTus)

    Job Locations US-MA-Lexington
    Job ID
  • Overview

    AgenTus (Lexington, MA) is seeking a creative and innovative Scientist/Sr. Scientist to join the Molecular Biology group. The successful candidate will work as part of an integrated, cross-site team to craft materials and processes that enable the validation of optimal targeting molecules (CARs and TCRs) for cellular therapeutics.  Come join our small team and work at an exciting start-up in the field of adoptive cell therapy!


    The successful candidate will work as part of a core team to create and characterize targeting molecules, including TCRs and CARs, that will enable the development of novel cellular therapeutics. The candidate will be expected to work independently and as part of a cross-functional group to design, engineer and generate DNA constructs, viral vectors and other gene delivery methods.  We are looking for an innovative thinker to develop and optimize higher-throughput processes for cloning and functionally testing the biological activity of new molecules in primary human cells.  Work will include plasmid design and construction, molecular engineering, retro/lentiviral vector production and cell-based immunologic assays.  The candidate should have the ability to independently troubleshoot technical issues and develop optimized processes for critical tasks. This position has the potential to lead a team of 1-2 research associates. 


    • A Ph.D. in molecular/cellular biology, immunology or related field with a minimum of 3 years of industry experience.
    • Experience with cellular therapy processes including molecular cloning, gene delivery into primary immune cells and immunology-based assays is preferred.
    • Specific knowledge of Gibson Assembly cloning procedures and/or flow cytometry methods is a plus.
    • Ability to interact with a diverse group of scientists in a collaborative environment.
    • Excellent analytical and communication skills are important for this position.


    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed